AOM INT'L (00381) Subsidiary Plans to Establish Yingyang Intelligent Technology Co., Ltd. with Joint Venture Partner to Build a Global Health Data Asset Operations Platform
AOM INT'L (00381) announced that its wholly-owned subsidiary, Kiu Hung Investment (Asia) Limited (Kiu Hung Investment), and a joint venture partner have recently jointly contributed capital to establish Yingyang Intelligent Technology Co., Ltd. (the joint venture company).
AOM INT'L (00381) announced that its wholly-owned subsidiary, Qiaoxiong Investment (Asia) Limited ("Qiaoxiong Investment"), together with a joint venture partner, have recently jointly contributed capital to establish Yingyang Intelligent Technology Co., Ltd. (the "JV Company").
The established JV Company will build a global health data asset operations platform for the Group, with the joint venture partner being solely responsible for actual operations. The cooperation integrates the advantageous resources of both parties, combining the Harvard core technology, AI smart ring, and leading "Health Data Assetization (RWA) and SaaS model" owned by the joint venture partner with the Company's health consumer product projects including Chinese herbal medicine, tea, and yellow rice wine for restructuring. The combination of the two can rapidly transform technology into physical revenue and digital assets.
The Company will mainly contribute listed company credit, compliant disclosure channels, and provide Hong Kong office space, licenses, and other compliant operating qualifications, while also appointing one director and a finance officer to control funds and risk management. The joint venture partner will be responsible for introducing the supply chain of anti-aging products and AI hardware, core intellectual property rights, R&D team, and global channels, and will appoint a team to be fully responsible for the operations of the JV Company.
Catering to the national strategic opportunity of "proactive health and aging," the joint venture partner has deeply participated in national key R&D programs. The Company's cooperation with it enables direct entry into the huge market of medical-grade out-of-hospital follow-up and digital health services representing future trends.
The Board believes that the establishment of the JV Company aligns with the Group's investment strategy of seeking business opportunities and intends to invest in quality businesses with good potential that can expand the Group's operations. The establishment of the JV Company will provide an opportunity for the Company to diversify the Group's revenue sources and enhance shareholder value.
Related Articles

BII TRANS TECH (01522) Appoints Li Yi as Non-Executive Director

ADWAY (06189) proposes to appoint CCTH CPA (Hong Kong) Limited as the new auditor.

KN HOSPITAL (02120) repurchased 68,600 shares on October 22 for approximately HK$779,800.
BII TRANS TECH (01522) Appoints Li Yi as Non-Executive Director

ADWAY (06189) proposes to appoint CCTH CPA (Hong Kong) Limited as the new auditor.

KN HOSPITAL (02120) repurchased 68,600 shares on October 22 for approximately HK$779,800.






